Huntington's disease (HD) is a severe neurodegenerative disorder manifesting as progressive impairment of motor function, cognitive decline, psychiatric symptoms, and immunological and endocrine dysfunction. We explored the consistency of blood transcriptomic biomarkers in HD based on a novel Slovene patient cohort and expert review of previous studies. HumanHT-12 v4 BeadChip microarrays were performed on the whole blood samples of a cohort of 23 HD mutation carriers and 23 controls to identify differentially expressed (DE) transcripts. In addition, we performed an expert review of DE transcripts identified in comparable HD studies from whole blood, to identify any consistent signature of HD. In the Slovene cohort, we identified 740 DE transcripts (p < 0.01 and a false discovery rate (FDR) of <0.1) of which 414 were downregulated and 326 were upregulated. Pathway analyses of DE transcripts showed enrichment for pathways involved in systemic, rather than neural processes in HD. With an expert review of comparable studies, we have further identified 15 DE transcripts shared by 3 studies. We suggest transcriptomic changes in blood reflect systemic changes in HD pathogenesis, rather than being a direct result of the neuropathological processes in the central nervous system during HD progression, and thus, have limited value as disease biomarkers.
Get full access to this article
View all access options for this article.
References
1.
BarkleyDS, HardiwidjajaS, and MenkesJH. (1977). Abnormalities in growth of skin fibroblasts of patients with Huntington's disease. Ann Neurol, 1, 426–430.
2.
BezprozvannyI, and HaydenMR. (2004). Deranged neuronal calcium signaling and Huntington disease. Biochem Biophys Res Commun, 322, 1310–1317.
3.
BjörkqvistM, WildEJ, ThieleJ, et al. (2008). A novel pathogenic pathway of immune activation detectable before clinical onset in Huntington's disease. J Exp Med, 205, 1869–1877.
4.
BoroveckiF, LovrečićL, ZhouJ, et al. (2005). Genome-wide expression profiling of human blood reveals biomarkers for Huntington's disease. Proc Natl Acad Sci, 102, 11023–11028.
5.
ByrneLM, RodriguesFB, BlennowK, et al. (2017). Neurofilament light protein in blood as a potential biomarker of neurodegeneration in Huntington's disease: A retrospective cohort analysis. Lancet Neurol, 16, 601–609.
6.
CescaF, BregantE, PeterlinB, et al. (2015). Evaluating the SERCA2 and VEGF mRNAs as potential molecular biomarkers of the onset and progression in Huntington's disease. PLoS One, 10, e0125259.
7.
ChangKH, ChenYC, WuYR, et al. (2012). Downregulation of genes involved in metabolism and oxidative stress in the peripheral leukocytes of Huntington's disease patients. PLoS One, 7, e46492.
8.
ChengML, ChangKH, WuYR, et al. (2016).Metabolic disturbances in plasma as biomarkers for Huntington's disease. J Nutr Biochem, 31, 38–44.
9.
CornettJ, CaoF, WangCE, et al. (2005). Polyglutamine expansion of huntingtin impairs its nuclear export. Nat Genet, 37, 198–204.
10.
CuiL, JeongH, BoroveckiF, et al. (2006). Transcriptional repression of PGC-1alpha by mutant huntingtin leads to mitochondrial dysfunction and neurodegeneration. Cell, 127, 59–69.
11.
DisatnikMH, JoshiAU, SawNL, et al. (2016). Potential biomarkers to follow the progression and treatment response of Huntington's disease. J Exp Med, 213, 2655–2669.
12.
DowieMJ, ScotterEL, MolinariE, et al. (2010). The therapeutic potential of G-protein coupled receptors in Huntington's disease. Pharmacol Ther, 128, 305–323.
13.
DuP, KibbeW, and LinSM (2008). Lumi: A pipeline for processing Illumina microarray. Bioinformatics, 24, 1547–1548.
14.
DunningMJ, SmithML, RitchieME, et al. (2007). Beadarray: R classes and methods for Illumina bead-based data. Bioinformatics, 23, 2183–2184.
15.
EsseltineJL, and FergusonSS. (2013). Regulation of G protein-coupled receptor trafficking and signaling by Rab GTPases. Small GTPases, 4, 132–135.
16.
FanMM, and RaymondLA. (2007). N-methyl-D-aspartate (NMDA) receptor function and excitotoxicity in Huntington's disease. Prog Neurobiol, 81, 272–293.
17.
GoetzI, RobertsE, and ComingsDE. (1975). Fibroblasts in Huntington's disease. N Engl J Med, 293, 1225–1227.
18.
HarjesP, and WankerEE. (2003). The hunt for huntingtin function: Interaction partners tell many different stories. Trends Biochem Sci, 28, 425–433.
19.
HedreenJC, PeyserCE, FolsteinSE, and RossCA. (1991). Neuronal loss in layers V and VI of cerebral cortex in Huntington's disease. Neurosci Lett, 133, 257–261.
20.
Hensman MossDJ, FlowerMD, LoKK, et al. (2017). Huntington's disease blood and brain show a common gene expression pattern and share an immune signature with Alzheimer's disease. Sci Rep, 7, e044849.
21.
HodgesA, StrandAD, AragakiAK, et al. (2006). Regional and cellular gene expression changes in human Huntington's disease brain. Hum Mol Genet, 15, 965–977.
22.
HuY, ChopraV, ChopraR, et al. (2011). Transcriptional modulator H2A histone family, member Y (H2AFY) marks Huntington disease activity in man and mouse. Proc Natl Acad Sci U S A, 108, 17141–17146.
23.
Huntington's Disease Collaborative Research Group. (1993). A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. The Huntington's Disease Collaborative Research Group. Cell, 72, 971–983.
KimSY, and VolskyDJ. (2005). PAGE: Parametric analysis of gene set enrichment. BMC Bioinformatics, 6, 144.
29.
Krzysztoń-RussjanJ, ZielonkaD, JackiewiczJ, et al. (2013). A study of molecular changes relating to energy metabolism and cellular stress in people with Huntington's disease: Looking for biomarkers. J Bioenerg Biomembr, 45, 71–85.
30.
KwanW, TragerU, DavalosD, et al. (2012). Mutant huntingtin impairs immune cell migration in Huntington disease. J Clin Invest, 122, 4737–4747.
31.
LanskaDJ, LanskaMJ, LavineL, et al. (1988). Conditions associated with Huntington's disease at death. Arch Neurol, 45, 878–884.
32.
LiS, and LiXJ. (2006). Multiple pathways contribute to the pathogenesis of Huntington disease. Mol Neurodegener, 1, 19.
33.
LovrečićL, KastrinA, KobalJ, et al. (2009). Gene expression changes in blood as a putative biomarker for Huntington's disease. Mov Disord, 24, 2277–2281.
34.
Luthi-CarterR, HansonS, StrandAD, et al. (2002). Dysregulation of gene expression in the R6/2 model of polyglutamine disease: Parallel changes in muscle and brain. Hum Mol Genet, 11, 1911–1926.
35.
MastrokoliasA, AriyurekY, GoemanJJ, et al. (2015). Huntington's disease biomarker progression profile identified by transcriptome sequencing in peripheral blood. Eur J Hum Genet, 23, 1349–1356.
36.
MiH, HuangX, MuruganujanA, et al. (2017). PANTHER version 11: Expanded annotation data from Gene Ontology and Reactome pathways, and data analysis tool enhancements. Nucleic Acids Res, 45, D183–D189.
37.
MihmMJ, AmannDM, SchanbacherBL, et al. (2007). Cardiac dysfunction in the R6/2 mouse model of Huntington's disease. Neurobiol Dis, 25, 297–308.
38.
MinaE, van Roon-MomW, HettneK, et al. (2016). Common disease signatures from gene expression analysis in Huntington's disease human blood and brain. Orphanet J Rare Dis, 11, 1–13.
39.
PattisonJS, SanbeA, MaloyanA, et al. (2008). Cardiomyocyte expression of a polyglutamine preamyloid oligomer causes heart failure. Circulation, 117, 2743–2751.
RunneH, KuhnA, WildEJ, et al. (2007). Analysis of potential transcriptomic biomarkers for Huntington's disease in peripheral blood. Proc Natl Acad Sci U S A, 104, 14424–14429.
42.
RunneH, RégulierE, KuhnA, et al. (2008). Dysregulation of gene expression in primary neuron models of Huntington's disease shows that polyglutamine-related effects on the striatal transcriptome may not be dependent on brain circuitry. J Neurosci, 28, 9723–9731.
43.
SalehN, MoutereauS, DurrA, et al. (2009). Neuroendocrine disturbances in Huntington's disease. PLoS One, 4, e4962.
44.
Sánchez-LópezF, TassetI, AgüeraE, et al. (2012). Oxidative stress and inflammation biomarkers in the blood of patients with Huntington's disease. Neurol Res, 34, 721–724.
45.
SenNE, DrostJ, GispertS, et al. (2016). Search for SCA2 blood RNA biomarkers highlights Ataxin-2 as strong modifier of the mitochondrial factor PINK1 levels. Neurobiol Dis, 96, 115–126.
46.
SeoH, SonntagKC, and IsacsonO. (2004). Generalized brain and skin proteasome inhibition in Huntington's disease. Ann Neurol, 56, 319–328.
47.
SubramanianA, TamayoP, MoothaVK, et al. (2005). Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide. Proc Natl Acad Sci U S A, 102, 15545–15550.
48.
SugarsKL, and RubinszteinDC. (2003). Transcriptional abnormalities in Huntington's disease. Trends Genet, 19, 233–238.
49.
TaiYF, PaveseN, GerhardA, et al. (2007). Microglial activation in presymptomatic Huntington's disease gene carriers. Brain, 130, 1759–1766.
50.
TobinAJ, and SignerER. (2000). Huntington's disease: The challenge for cell biologists. Trends Cell Biol, 10, 531–536.
51.
TrägerU, and TabriziSJ. (2013). Peripheral inflammation in neurodegeneration. J Mol Med (Berl), 91, 673–681.
52.
TrushinaE, and McMurrayCT. (2007). Oxidative stress and mitochondrial dysfunction in neurodegenerative diseases. Neuroscience, 145, 1233–1248.
53.
TrushinaE, HeldebrantMP, Perez-TerzicCM, et al. (2003). Microtubule destabilization and nuclear entry are sequential steps leading to toxicity in Huntington's disease. Proc Natl Acad Sci U S A, 100, 12171–12176.
54.
TurnerC, CooperJM, and SchapiraAH. (2007). Clinical correlates of mitochondrial function in Huntington's disease muscle. Mov Disord, 22, 1715–1721.
55.
van BlitterswijkM, DeJesus-HernandezM, and RademakersR. (2012). How do C9ORF72 repeat expansions cause amyotrophic lateral sclerosis and frontotemporal dementia: Can we learn from other noncoding repeat expansion disorders?. Curr Opin Neurol, 25, 689–700.
56.
van der BurgJMM, BjörkqvistM, and BrundinP. (2009). Beyond the brain: Widespread pathology in Huntington's disease. Lancet Neurol, 8, 765–774.
57.
VonsattelJPG. (2008). Huntington disease models and human neuropathology: Similarities and differences. Acta Neuropathol, 115, 55–69.
58.
ZadelM, MaverA, KovandaA, et al. (2018) Transcriptomic biomarcers for Huntington's Disease: Are gene expression signatures in whole blood reliable biomarkers?. OMICS, 22, in press. DOI: 10.1089/omi.2017.0206.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
